Prions Bio Tech

Belgaum, India Founded: 2010 • Age: 16 yrs Listed
Manufactures organic fertilizers, aquaculture products, and waste management solutions for sustainable applications.
Request Access
Report Incorrect Data
Page last updated

About Prions Bio Tech

Prions Bio Tech is a publicly listed company based in Belgaum (India) founded in 2010. It manufactures organic fertilizers, aquaculture products, and waste management solutions for sustainable applications. It operates on a B2B model in Environment and Agriculture sectors. The company has 3,256 employees. Its Indian entity Indiamart Intermesh Limited reported revenue of ₹1,773 Cr. Prions Bio Tech offers products and services including Waste Decomposer Inoculum, Bacillus Coagulans Probiotic Powder, Sewage Treatment Chemical, Humic Acid Liquid, and Crude Oil Bioremediation Bacteria. Its focus areas include Environmental, Waste Management, Bioremediation and Solid Waste.

Company details

Prions Biotech is a biotechnology company based in Belagavi, Karnataka, India, specializing in manufacturing and exporting products like organic fertilizers, animal health supplements, and wastewater treatment chemicals. It focuses on innovative solutions for agriculture, aquaculture, and environmental sustainability through microbial cultures and enzymes. The company serves industries by providing eco-friendly alternatives to traditional methods, emphasizing quality and global export standards.

  • Headquarters Belgaum, India
  • Employees 3,256
  • Stage Public
  • Sectors
    Environment
    Agriculture
  • Phone
    •••• ••••
  • Website prionsbiotech.in
  • Legal Name Indiamart Intermesh Limited
  • Date of Incorporation 13 Sep, 1999
  • Jurisdiction New Delhi, Delhi, India
Operational Areas
Environment → Waste & Water Management Systems
Agriculture → Crop Inputs & Fertilizers
Key Metrics
  • Market Cap
    ₹9,287 Cr

    INDIAMART · NSE

  • Share Price
    ₹1,487.20

    -3.69% today

  • Revenue
    ₹1,569 Cr

    FY 2025-26 · +13.0% YoY

  • EBITDA
    ₹475 Cr

    Margin 30.3%

  • Net Profit
    ₹475 Cr

    FY 2025-26 · -10.1% YoY

  • P/E (TTM)
    18.9x

    P/B 4.1x

  • ROE
    20.7%

    ROCE 21.4%

  • Debt / Equity
    0.01

    Interest cover 0.7x

  • Employee Count
    3,256

Products & Services of Prions Bio Tech

Prions Bio Tech offers a comprehensive portfolio of products and services, including Waste Decomposer Inoculum, Bacillus Coagulans Probiotic Powder, Sewage Treatment Chemical, Humic Acid Liquid, and Crude Oil Bioremediation Bacteria.

Waste Decomposer Inoculum
Organic Fertilizer

Inoculum for decomposing organic waste effectively

Bacillus Coagulans Probiotic Powder
Animal Health Product

Probiotic powder for enhancing animal gut health

Sewage Treatment Chemical
Waste Management

Chemical for treating sewage and wastewater

Humic Acid Liquid
Agriculture Product

Liquid for improving soil fertility and plant growth

Crude Oil Bioremediation Bacteria
Environmental Product

Bacteria for bioremediation of crude oil spills

Agrovita Organic Growth Promoter
Plant Nutrient

Promoter for organic growth in agricultural plants

Cotton Growth Promoter
Agriculture Product

Enhancer for cotton plant development and yield

Board of directors of Indiamart Intermesh Limited (Prions Bio Tech)

Indiamart Intermesh Limited is the primary company behind Prions Bio Tech. The board of Indiamart Intermesh Limited currently have 8 directors; the longest-serving is Dinesh Chandra Agarwal, appointed in 1999. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Dinesh Chandra Agarwal
DIN 00191800
Managing Director13 Sep 199927 yrs 1 moIndiamart Intermesh Limited
Brijesh Kumar Agrawal
DIN 00191760
Whole-time director13 Sep 199927 yrs 1 moIndiamart Intermesh Limited
Vivek Narayan Gour
DIN 00254383
Director30 Apr 20188 yrs 6 moIndiamart Intermesh Limited
Pallavi Dinodia Gupta
DIN 06566637
Director20 Oct 20224 yrsIndiamart Intermesh Limited
Manoj Bhargava
DIN 08267536
Whole-time director21 Jan 20251 yr 9 moIndiamart Intermesh Limited
Manish Vij
DIN 00505422
Director21 Jan 20251 yr 9 moIndiamart Intermesh Limited
Sandeep Kumar Barasia
DIN 01432123
Director29 Apr 20251 yr 6 moIndiamart Intermesh Limited
Vasuta Agarwal
DIN 07480674
Director18 Jul 20251 yr 3 moIndiamart Intermesh Limited

IPO & Listings of Prions Bio Tech

Prions Bio Tech is a publicly listed company on the NSE with ticker symbol INDIAMART in India, operating in the E-Commerce/App based Aggregator sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: INDIAMART
  • Listed entityIndiamart Intermesh Limited
  • Exchange sectorE-Commerce/App based Aggregator

Financials of Prions Bio Tech

Exchange-reported figures of Indiamart Intermesh Limited, the listed company behind Prions Bio Tech (NSE: INDIAMART).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,569 Cr
+13.0% YoY
EBITDA
₹475 Cr
+0.3% YoY
Profit After Tax
₹475 Cr
-10.1% YoY
Net Worth
₹2,400 Cr
+9.8% YoY
Total Assets
₹3,214 Cr
+11.8% YoY
Total Debt
₹23.10 Cr
-30.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,5691,3881,197985753670639
Revenue growth+13.0%+16.0%+21.5%+30.8%+12.5%+4.8%-
EBITDA475474289230296326167
EBITDA margin+30.3%+34.1%+24.2%+23.3%+39.2%+48.6%+26.2%
Profit before tax648706454371390389211
Net profit475528335283297279147
Net profit margin+30.3%+38.0%+28.0%+28.7%+39.5%+41.7%+23.1%
EPS (₹)79.0091.7855.7192.8297.4192.2951.04
Balance sheet
Total assets3,2142,8752,3502,5802,2851,960648
Net worth2,4002,1851,7362,0581,8741,611275
Total debt23.1033.0440.6745.9156.2863.4276.51
Cash & bank91.2084.3910158.2876.8277.7323.86
Net working capital(1,191)(1,064)(908)(753)(509)(363)(427)
Cash flow
Cash from operations694623559476402322261
Cash from investing(347)(486)162(324)(335)(1,338)(233)
Cash from financing(340)(148)(695)(143)(57.52)1,038(51.30)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue429414404402391372355354
Revenue growth (YoY)+9.6%+11.4%+13.9%+13.4%+12.5%+12.3%--
Other income(7.60)107(33.90)13510.2092.4010944.90
EBITDA144132120120116119119124
EBITDA margin+33.6%+31.8%+29.7%+29.8%+29.7%+32.1%+33.6%+35.1%
Depreciation6.406.407.007.307.206.908.308.30
Interest0.500.500.600.700.701.001.701.80
Profit before tax12923278.40247119204218159
Tax38.6059.5028.2058.7035.9050.4037.5038.00
Net profit90.8017250.2018882.70154181121
EPS (₹)15.0528.568.3331.2413.7125.5230.0620.13
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,4431,3201,139939751665624
Revenue growth+9.3%+15.9%+21.3%+25.1%+12.9%+6.7%-
EBITDA520513334256312333166
EBITDA margin+36.1%+38.9%+29.3%+27.3%+41.6%+50.1%+26.6%
Profit before tax694773475345403396210
Net profit525598362276310286152
Net profit margin+36.4%+45.3%+31.8%+29.4%+41.2%+43.0%+24.4%
EPS (₹)87.41101.2060.4289.01101.4194.5750.63
Balance sheet
Total assets3,3102,9342,3422,5492,3031,966647
Net worth2,5422,2761,7702,0641,8921,617274
Total debt23.1033.0440.6745.9156.2863.4276.51
Cash & bank77.3868.9481.3750.2872.5672.6119.77
Net working capital(1,141)(1,021)(898)(741)(513)(368)(430)
Cash flow
Cash from operations668614545464407326264
Cash from investing(347)(492)181(316)(339)(1,343)(236)
Cash from financing(313)(135)(695)(143)(57.50)1,038(51.30)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue389376368368360346336337
Revenue growth (YoY)+8.0%+8.6%+9.7%+9.1%+8.6%+9.8%--
Other income(8.60)88.10(33.90)1328.0084.4014822.90
Total expenses233227234232245212203193
EBITDA156149135136115135133144
EBITDA margin+40.2%+39.7%+36.6%+37.0%+31.9%+38.9%+39.5%+42.7%
Depreciation2.602.603.203.603.603.505.005.10
Interest0.600.500.600.600.700.800.900.90
Profit before tax14523496.90264119215275161
Tax38.3058.2027.3058.0035.2048.8043.6036.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue429414404402391372355354
Revenue growth (YoY)+9.6%+11.4%+13.9%+13.4%+12.5%+12.3%--
Other income(7.60)107(33.90)13510.2092.4010944.90
EBITDA144132120120116119119124
EBITDA margin+33.6%+31.8%+29.7%+29.8%+29.7%+32.1%+33.6%+35.1%
Depreciation6.406.407.007.307.206.908.308.30
Interest0.500.500.600.700.701.001.701.80
Profit before tax12923278.40247119204218159
Tax38.6059.5028.2058.7035.9050.4037.5038.00
Net profit90.8017250.2018882.70154181121
EPS (₹)15.0528.568.3331.2413.7125.5230.0620.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,5691,3881,197985753670639
Revenue growth+13.0%+16.0%+21.5%+30.8%+12.5%+4.8%-
Other income20427221118111286.5868.59
Total expenses1,094915908755458344472
Employee cost693601544425268205267
EBITDA475474289230296326167
EBITDA margin+30.3%+34.1%+24.2%+23.3%+39.2%+48.6%+26.2%
Depreciation28.4532.9436.4631.0811.9516.0721.15
Interest2.987.418.918.155.406.663.28
Profit before tax648706454371390389211
Tax17315512087.4592.8311064.04
Net profit475528335283297279147
Net profit margin+30.3%+38.0%+28.0%+28.7%+39.5%+41.7%+23.1%
EPS (₹)79.0091.7855.7192.8297.4192.2951.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital60.0860.0159.9530.5830.5530.3228.88
Reserves & surplus2,3402,1251,6762,0281,8441,581246
Shareholders' funds (net worth)2,4002,1851,7362,0581,8741,611275
Minority interest0.000.000.000.000.000.000.00
Secured loans0.000.000.000.000.000.000.00
Unsecured loans23.1033.0440.6745.9156.2863.4276.51
Total debt23.1033.0440.6745.9156.2863.4276.51
Total liabilities3,2142,8752,3502,5802,2851,960648
Assets
Gross block658652644630106106118
Net block49451553655356.0765.0785.63
Capital work in progress0.000.470.500.180.180.180.18
Investments3,7923,4532,7462,7842,7222,254901
Inventories0.000.000.000.000.000.000.00
Sundry debtors5.503.974.787.061.331.251.68
Cash & bank balances91.2084.3910158.2876.8277.7323.86
Loans & advances67.4959.1041.9626.2061.2788.3022.53
Total current assets16414714891.5413916748.07
Total current liabilities1,3551,2111,056844648530475
Net working capital(1,191)(1,064)(908)(753)(509)(363)(427)
Total assets3,2142,8752,3502,5802,2851,960648
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash73.4884.8058.1149.5540.1216.9440.20
Net cash from operating activities694623559476402322261
Net cash from investing activities(347)(486)162(324)(335)(1,338)(233)
Net cash from financing activities(340)(148)(695)(143)(57.52)1,038(51.30)
Net change in cash6.93(11.32)26.708.569.4323.18(23.26)
Closing cash91.2084.3910158.2876.8277.7323.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.0%+16.0%+21.5%+30.8%+12.5%+4.8%-
EBITDA growth+0.3%+63.8%+25.7%-22.2%-9.2%+94.6%-
PBT growth-8.2%+55.3%+22.4%-4.9%+0.3%+84.2%+292.0%
Net income growth-10.1%+57.7%+18.2%-4.8%+6.6%+89.4%-
Revenue CAGR (3Y)+16.8%+22.6%+21.4%+15.5%+14.1%+17.7%+26.2%
EBITDA CAGR (3Y)+27.4%+17.0%-3.9%+11.2%+158.6%--
Profitability & leverage
Net income margin+30.3%+39.7%+27.9%+28.8%+39.5%+41.8%+23.1%
Return on capital employed+21.4%+27.3%+18.8%+15.6%+18.7%+27.8%+26.3%
Return on net worth+20.7%+28.1%+17.6%+14.4%+17.1%+26.3%+28.8%
Debt / equity0.010.020.020.030.030.070.18
Long-term debt / equity0.010.010.020.020.030.060.14
Interest cover0.671.683.534.101.902.152.24
Efficiency & per share
Fixed asset turnover2.392.141.882.687.095.989.24
Inventory turnover0.000.000.000.000.000.000.00
Debtors turnover331.37317.33202.16234.90584.10457.04567.87
EPS (₹)79.0091.7855.7192.8297.4192.2951.04
Dividend per share (₹)60.0050.0020.0020.002.0015.0010.00
Book value per share (₹)399.50364.18289.60673.17613.38531.3695.25
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue389376368368360346336337
Revenue growth (YoY)+8.0%+8.6%+9.7%+9.1%+8.6%+9.8%--
Other income(8.60)88.10(33.90)1328.0084.4014822.90
Total expenses233227234232245212203193
EBITDA156149135136115135133144
EBITDA margin+40.2%+39.7%+36.6%+37.0%+31.9%+38.9%+39.5%+42.7%
Depreciation2.602.603.203.603.603.505.005.10
Interest0.600.500.600.600.700.800.900.90
Profit before tax14523496.90264119215275161
Tax38.3058.2027.3058.0035.2048.8043.6036.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,4431,3201,139939751665624
Revenue growth+9.3%+15.9%+21.3%+25.1%+12.9%+6.7%-
Other income19128417011310885.1668.41
Total expenses923807805682439332458
Employee cost634553507399263199255
EBITDA520513334256312333166
EBITDA margin+36.1%+38.9%+29.3%+27.3%+41.6%+50.1%+26.6%
Depreciation13.8720.5224.5819.2711.9015.8720.92
Interest2.713.754.274.685.406.663.28
Profit before tax694773475345403396210
Tax16916611273.1192.8310963.78
Net profit525598362276310286152
Net profit margin+36.4%+45.3%+31.8%+29.4%+41.2%+43.0%+24.4%
EPS (₹)87.41101.2060.4289.01101.4194.5750.63
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital60.0860.0159.9530.5830.5530.3228.88
Reserves & surplus2,4822,2161,7102,0341,8621,586246
Shareholders' funds (net worth)2,5422,2761,7702,0641,8921,617274
Secured loans0.000.000.000.000.000.000.00
Unsecured loans23.1033.0440.6745.9156.2863.4276.51
Total debt23.1033.0440.6745.9156.2863.4276.51
Total liabilities3,3102,9342,3422,5492,3031,966647
Assets
Gross block134133131117105105116
Net block20.8833.2647.3853.1956.0364.9985.22
Capital work in progress0.000.000.500.180.180.180.18
Investments4,3263,9443,1993,2242,7452,267906
Inventories0.000.000.000.000.000.000.00
Sundry debtors1.121.681.351.581.331.251.10
Cash & bank balances77.3868.9481.3750.2872.5672.6119.77
Loans & advances30.4432.9127.4318.6359.8087.1220.94
Total current assets10910411070.4913416141.81
Total current liabilities1,2501,1251,009812647529472
Net working capital(1,141)(1,021)(898)(741)(513)(368)(430)
Total assets3,3102,9342,3422,5492,3031,966647
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash68.6881.1450.1145.2835.0112.9035.91
Net cash from operating activities668614545464407326264
Net cash from investing activities(347)(492)181(316)(339)(1,343)(236)
Net cash from financing activities(313)(135)(695)(143)(57.50)1,038(51.30)
Net change in cash8.38(12.46)31.034.8310.2722.10(23.01)
Closing cash77.3868.9481.3750.2872.5672.6119.77
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.3%+15.9%+21.3%+25.1%+12.9%+6.7%-
EBITDA growth+1.3%+53.8%+30.2%-17.9%-6.4%+101.1%-
PBT growth-10.2%+62.9%+37.5%-14.3%+1.7%+88.6%+353.1%
Net income growth-12.2%+65.4%+31.3%-11.0%+8.3%+88.2%-
Revenue CAGR (3Y)+15.4%+20.7%+19.6%+14.6%+14.7%+18.1%+26.4%
EBITDA CAGR (3Y)+26.6%+18.1%+0.1%+15.6%+179.3%--
Profitability & leverage
Net income margin+36.4%+46.0%+31.8%+29.0%+41.3%+43.1%+23.5%
Return on capital employed+22.3%+29.4%+19.6%+14.4%+19.1%+28.2%+26.1%
Return on net worth+21.8%+30.0%+18.9%+13.8%+17.7%+26.9%+28.7%
Debt / equity0.010.020.020.030.030.070.18
Long-term debt / equity0.010.010.020.020.030.060.14
Interest cover0.540.761.381.971.802.102.26
Efficiency & per share
Fixed asset turnover10.809.979.168.437.146.019.18
Inventory turnover0.000.000.000.000.000.000.00
Debtors turnover1,030.57871.33777.47645.24581.99566.00860.01
EPS (₹)87.41101.2060.4289.01101.4194.5750.63
Dividend per share (₹)60.0050.0020.0020.002.0015.0010.00
Book value per share (₹)423.03379.33295.31675.11619.30533.2695.06

Web traffic of Prions Bio Tech

The website of Prions Bio Tech (prionsbiotech.in) receives about 1.4K visits a month.

  • Monthly visits
    1.4K

    ▲ 23.7% vs previous month

Top companies in Waste & Water Management Systems

3 companies that operate in the same segment as Prions Bio Tech (Waste & Water Management Systems) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Ecozen Solutions
Provider of climate-smart deeptech solutions for renewable energy and sustainable agriculture
2010Pune, Maharashtra, IndiaUSD 76.38 MUSD 56.11 M702
DrinkPrime
Provider of smart water purifier rental and maintenance services
2016Bengaluru, Karnataka, IndiaUSD 19.29 MUSD 3.62 M
Attero
Tech-based solid waste management and recycling solutions are provided.
2008Noida, Uttar Pradesh, IndiaUSD 31.1 MUSD 52.13 M106
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Prions Bio Tech

Indiamart: Co Intermesh Reports 10% Yearly Revenue Increase To ₹429 Crores; Customer Collections Reach ₹443 Crores, Deferred Revenue Rises 16% To ₹2,029 Crores, And Net Profit Stands At ₹91 Crores.
Exchange Update • 1 day ago
IndiaMART: Nomura on IndiaMART Upgrades to Neutral, Target Price Rs 1,840; subscriber additions continued to decline slightly in Q2, making product improvements critical for medium-term growth. A meaningful recovery in subscriber additions is needed for significant stock upside, while falling unique business enquiries pose a key downside risk.
Exchange Update • 4 days ago
Indiamart: Company Sets Long-Term EBITDA Margin Goal At 33%, While Current Q2 FY27 Margins Are Higher At 37% Due To Lower Sales Investment. Management Believes Value And Volume Growth Will Align In The Future, Unlike The Past Two To Three Years Which Were Primarily Value-Driven.
Exchange Update • 4 days ago
Indiamart Intermesh: Aims For 10% Revenue Growth In FY27
Exchange Update • 4 days ago
INDIAMART: Q2 CONS NET PROFIT 908M RUPEES VS 827M (YOY); EST 1.26B
Exchange Update • 5 days ago
INDIAMART: Q2 EBITDA 1.6B RUPEES VS 1.3B (YOY); Q2 EBITDA MARGIN 37.14% VS 33.17% (YOY)
Exchange Update • 5 days ago
INDIAMART: Q2 REVENUE 4.3B RUPEES VS 3.91B (YOY)
Exchange Update • 5 days ago
INDIAMART: Q2 REVENUE GROWTH AT 10% VS FY27 GUIDANCE OF 10–12%
Exchange Update • 5 days ago
Nifty Retail Index stocks: New indicator for New India: 25 stocks whose numbers can reveal what is in store for the economy and the stock market - The Economic Times
Economic Times • 1 month ago
Deals Digest: PE-VC deal count, funding hold steady, M&A activity slows
VCCircle • 3 months ago
Premium access

Complete news archive for Prions Bio Tech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Prions Bio Tech

Prions Bio Tech was founded in 2010.

Prions Bio Tech is headquartered in Belgaum, India. It is registered at Belgaum, Karnataka, India.

Prions Bio Tech has 3,256 employees.

The primary company behind Prions Bio Tech, Indiamart Intermesh Limited, reported revenue of ₹1,773 Cr for FY 2026, up 13% year on year.

Prions Biotech is a biotechnology company based in Belagavi, Karnataka, India, specializing in manufacturing and exporting products like organic fertilizers, animal health supplements, and wastewater treatment chemicals. It focuses on innovative solutions for agriculture, aquaculture, and environmental sustainability through microbial cultures and enzymes. The company serves industries by providing eco-friendly alternatives to traditional methods, emphasizing quality and global export standards.

Prions Bio Tech offers Waste Decomposer Inoculum, Bacillus Coagulans Probiotic Powder, Sewage Treatment Chemical, Humic Acid Liquid, and 3 more products and services.

Yes, Prions Bio Tech is publicly traded on NSE under the ticker symbol INDIAMART.

Prions Bio Tech operates through Indiamart Intermesh Limited.

The legal entities of Prions Bio Tech currently have 9 directors, including Dinesh Chandra Agarwal, Brijesh Kumar Agrawal, Pallavi Dinodia Gupta and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available